275 filings
Page 7 of 14
8-K
pk53vlxtfsmbwjuthae
13 May 21
Other Events
4:19pm
8-K
01i0ruw
12 May 21
Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update
7:35am
8-K
v57h1n696ir1f8
14 Apr 21
Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
7:35am
8-K
b630mq
6 Apr 21
Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
7:32am
8-K
81s8qb1zwy8
30 Mar 21
Moleculin Receives FDA Approval of Fast Track
7:30am
8-K
z7b0kvc958sjw waf
24 Mar 21
Moleculin Biotech, Inc. Reports Financial Results
7:31am
8-K
wagd047h5vizivm1qc3
8 Mar 21
Regulation FD Disclosure
4:15pm
8-K
ogq7ysnb b7hzf
19 Feb 21
Other Events
5:01pm
8-K
2pd5qak vk2qv4
10 Feb 21
Moleculin Announces Full Exercise of Over-Allotment Option
4:15pm
8-K
eh7pe o2z
8 Feb 21
Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases
7:29am
8-K
4a7 ypxty
4 Feb 21
Moleculin Announces Proposed Underwritten Public Offering
4:07pm
8-K/A
it82lxiq
2 Feb 21
Material Modifications to Rights of Security Holders
9:41pm
8-K
oin925t
2 Feb 21
Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
7:29am
8-K
5nv0lxv
1 Feb 21
Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial
7:29am
8-K
ku9h6scygo ec
29 Jan 21
Moleculin Announces Reverse Stock Split
9:15am
8-K
47u8bpga4cx
11 Jan 21
Regulation FD Disclosure
7:31am
8-K
hhsct0q
29 Dec 20
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
7:29am
8-K
sats bd9fvgb
17 Dec 20
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
7:29am
8-K
x4img5 axg
3 Dec 20
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference
7:29am
8-K
03ezu
1 Dec 20
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
4:15pm